This pole, located at Henri Mondor and Albert Chenevier Hospitals at Creteil, is composed of 7 teams whose principal investigative tool is the analysis of genomic expression.
These teams focus on three specific axes of research using common core facilities.

The "Molecular Virology and Immunology" research axis is driven by two teams working on virology, immunology and vaccinology involving the hepatitis viruses (Dr JM Pawlotsky) and HIV (Dr Y. Levy).
Their common objectives are to understand the virological and immunological mechanisms underlying the pathologies developed by target tissues (hepatocytes and lymphocytes) during viral attacks, to study the molecular mechanisms involved in the response to antiviral treatments and in the resistance to new drugs, and to develop novel therapeutic and vaccine-based approaches in this field.
The two teams share several resources, including an L3 laboratory, the genomics facility, a molecular virology facility and an immunomonitoring facility, in order to test and develop new therapeutic and vaccine-based strategies targeting these viruses.

An "Oncology" axis is dedicated to research on the molecular alterations that occur in different types of cancer, especially in lymphomas (Dr P. Gaulard) and cancers of the urogenital tract (Dr A. de la Taille).
The two teams aim to characterize specific gene expression patterns during the course of these illnesses, in order to identify new markers that could be of use in patient diagnosis, prognosis and follow-up, and to understand the pathophysiological mechanisms implicated in these cancers.
These teams work on translational research projects with the appropriate patient groups, under the framework of national-level treatment protocols.
The two teams share experimental approaches, and their work takes advantage of the genomics facility for the characterization of gene expression (in fact, this aspect is often "delocalized" for both teams).
In addition, the studies on lymphoma will benefit from the installation of a platform for diagnostic validation, and for the search for markers that predict response to new therapeutic strategies.

The "Genetic Diseases" axis brings together three groups that aim to identify and analyze genes whose expression is altered during the course of development (neurocristopathies), in cystic fibrosis and in the hemoglobinopathies (Dr M. Goossens), in different psychiatric disorders (bipolar disorder, schizophrenia, autism and obsessive-compulsive disorder) (Dr M. Leboyer) and in nephrotic syndromes (Dr D. Sahali).
These teams are skilled in the use of molecular biological techniques that permit the identification of the genes involved and an understanding of their function, a prerequisite for the development of the appropriate diagnostic and treatment options.
In addition, they rely on large groups of patients that they are currently following and/or have collected over a long period, through networks of collaborations that are often coordinated by the teams themselves.
These three teams have developed and manage a genomics facility that is at the disposal of the other teams of the IMRB.
The psychiatry team also coordinates the Thematic Research and Care Network (Réseau Thématique de Recherche et de Soins or RTRS) for Mental Health
(FondaMental Foundation), Dil Sahali is in charge of the rare diseases Reference Center for idiopathic nephrotic syndrome, and the Goossens team is in charge of the Reference Center for major sickle-cell syndromes.

Together, these seven teams possess the expertise necessary for the study of genes (human and viral), for the genomic and proteomic analyses required for a dissection of pathological processes, and for the development of targeted diagnostic and therapeutic approaches.